CDK12 and breast carcinoma: Specific cases, such as treatments targeting the ESR1 mutation in breast cancer, MSI and TMB-high in biliary tract cancer, and CDK12 mutation in head and neck cancer—detected exclusively through ctDNA but not in tissue samples—demonstrated partial responses (Fig 4C).